Department of Clinical Laboratory, Fujian Provincial Hospital South Branch, Fuzhou, Fujian, China.
Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China.
Epidemiol Infect. 2023 Oct 2;151:e173. doi: 10.1017/S0950268823001619.
We conducted a retrospective, analytical cross-sectional and single-centre study that included 190 hospitalised COVID-19 patients in the Fujian Provincial Hospital South Branch between December 2022 and January 2023 to analyse the correlation of viral loads of throat swabs with clinical progression and outcomes. To normalise the Ct value as quantification of viral loads, we used RNase P gene as internal control gene and subtracted the Ct value of SARS-CoV-2 N gene from the Ct value of RNase P gene, termed △Ct. Most patients were discharged (84.2%), and only 10 (5.6%) individuals who had a lower △Ct value died. The initial △Ct value of participants was also significantly correlated with some abnormal laboratory characteristics, and the duration time of SARS-CoV-2 was longer in patients with severe symptoms and a lower △Ct value at admission. Our study suggested that the △Ct value may be used as a predictor of disease progression and outcomes in hospitalised COVID-19 patients.
我们进行了一项回顾性、分析性的横断面和单中心研究,纳入了 2022 年 12 月至 2023 年 1 月期间在福建省立医院南院住院的 190 例 COVID-19 患者,以分析咽拭子病毒载量与临床进展和结局的相关性。为了使 Ct 值正常化作为病毒载量的定量,我们使用 RNase P 基因作为内参基因,并从 SARS-CoV-2 N 基因的 Ct 值中减去 RNase P 基因的 Ct 值,称为△Ct。大多数患者出院(84.2%),只有 10 名(5.6%)△Ct 值较低的患者死亡。参与者的初始△Ct 值也与一些异常的实验室特征显著相关,且症状严重和入院时△Ct 值较低的患者 SARS-CoV-2 持续时间更长。我们的研究表明,△Ct 值可作为住院 COVID-19 患者疾病进展和结局的预测指标。